文献速递胸部肿瘤放疗

大分割调强放疗联合同步化疗治疗局部晚期非小细胞肺癌:GASTO1011 II期前瞻性临床试验

Hypofractionated Intensity Modulated Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Prospective Clinical Trial (GASTO1011).
PubMed 文献 · Pract Radiat Oncol · 2021-06-20

结果显示客观缓解率97.8%,中位无进展生存期11.0个月,中位总生存期27.0个月,毒性可耐受。

要点

  • 分程大分割放疗联合同步化疗在局部晚期非小细胞肺癌中取得97.8%的客观缓解率。
  • 中位无进展生存期11.0个月,中位总生存期27.0个月。
  • 休息期后肺功能较好者总生存显著更优,肺功能检测是放疗计划和剂量递增的必要指标。

核心结论

  • 分程大分割放疗联合同步化疗在局部晚期非小细胞肺癌中取得有前景的缓解率和生存,毒性可耐受。

研究设计与样本

  • 入组要求FEV1/FVC%≥40%且DLCO%≥45%。
  • 放疗采用调强放疗技术,第一程51 Gy分17次,休息后对无进展且无持续≥2级毒性的患者给予15至18 Gy分5至6次推量。
  • 主要终点为无进展生存期,次要终点为总生存期。

主要发现

  • 全组中位随访29.5个月,生存者中位随访35.3个月。
  • 客观缓解率为97.8%,中位无进展生存期11.0个月,中位总生存期27.0个月。
  • 3级急性食管炎发生于15例(16.9%),3级急性肺炎发生于7例(7.9%)。
  • 3级晚期肺炎发生于2例(2.2%),5级晚期肺炎发生于1例(1.1%)。
  • 78例(87.6%)按方案完成分程大分割放疗联合同步化疗。

关键数值与推荐

  • 休息期后FEV1/FVC%≥80%、60%-79%、41%-59%三组2年总生存率分别为57.2%、56.9%、0%(P=.024)。
  • 休息期后DLCO%≥80%、60%-79%、45%-59%三组2年总生存率分别为70.4%、48.4%、37.5%(P=.049)。

临床怎么用

  • 分程大分割放疗联合同步化疗可作为局部晚期非小细胞肺癌的治疗选择,毒性可耐受。
  • 肺功能检测(FEV1/FVC%和DLCO%)应作为放疗计划和剂量递增的必要指标。

局限性

  • 本研究为单臂II期试验,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to explore the efficacy and toxicity of split-course hypofractionated radiation therapy with concurrent chemotherapy (HRT-CHT) in patients with locally advanced non-small cell lung cancer (LANSCLC) in this single-arm, phase II study. METHODS AND MATERIALS: Patients with LANSCLC were considered eligible if their forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC%) and carbon monoxide diffusing capacity (DLCO%) were ≥40% and ≥45%, respectively. HRT-CHT using the intensity modulated radiation therapy technique was administered with 51 Gy in 17 fractions as the first course followed by a break. Patients without disease progression or persistent ≥grade 2 toxicities had an HRT-CHT of 15 to 18 Gy in 5 to 6 fractions as a boost. The primary endpoint was progression-free survival, and the secondary endpoint was overall survival (OS). RESULTS: Eighty-nine patients were enrolled and analyzed. The median follow-up was 29.5 months for all patients and 35.3 months for the survivors. The objective response rate was 97.8%; the median progression-free survival and OS were 11.0 and 27.0 months, respectively. Grade 3 acute esophagitis/pneumonitis occurred in 15 (16.9%)/7 (7.9%) patients. Grade 3/5 late pneumonitis occurred in 2 (2.2%)/1 (1.1%) patients. Of the 78 (87.6%) who completed the split-course HRT-CHT per protocol, patients with better FEV1/FVC% and DLCO% after the break had significantly better OS (for the FEV/FVC1% ≥ 80% vs 60%-79% vs 41%-59% groups, 2-year OS values were 57.2% vs 56.9% vs 0%, respectively, P = .024; for the DLCO% ≥ 80% vs 60%-79% vs 45%-59% groups, 2-year OS values were 70.4% vs 48.4% vs 37.5%, respectively, P = .049). CONCLUSIONS: Split-course HRT-CHT achieved a promising response rate and survival with tolerable toxicity in LANSCLC. Pulmonary function tests are necessary indicators for radiation treatment planning and dose escalation.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Qiu B, Xiong M, Luo Y, et al. Hypofractionated Intensity Modulated Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Prospective Clinical Trial (GASTO1011). Pract Radiat Oncol. 2021. PMID: 34157448. doi:10.1016/j.prro.2021.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。